Compositions for use in treating and/or preventing type 2 diabetes, pre-diabetes, and/or a symptom thereof
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a novel composition and therapeutic to effectively treat and prevent type 2 diabetes and its symptoms, as existing treatments like metformin have limited efficacy and can disrupt the gut microbiome, leading to chronic systemic inflammation and insulin resistance.
Innovation Solution
A composition comprising Bacillus species, rice bran, L-cysteine, and high molecular weight low osmolality carbohydrates is used to modulate the gut microbiome, reducing glucose absorption and inflammation by metabolizing glucose and enhancing insulin sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If metformin is used to treat type 2 diabetes, then glycemic control is improved, but gut microbiome composition is disrupted leading to chronic systemic inflammation and insulin resistance
Solution Approach 1:
The patent introduces probiotic bacteria (Lactobacillus acidophilus, Bifidobacterium animalis, Saccharomyces boulardii) as intermediary organisms that mediate between the host and glucose metabolism. These probiotics directly colonize the gut, produce short-chain fatty acids, and modulate immune responses, thereby improving glycemic control through biological mechanisms rather than pharmacological intervention, thus avoiding the harmful disruption of gut microbiome composition caused by metformin
Solution Approach 2:
The patent changes the fundamental parameter of treatment approach from pharmacological inhibition (metformin) to probiotic supplementation. The composition specifies precise amounts of each probiotic strain (e.g., 1×10^9 CFU of Lactobacillus acidophilus, 1×10^9 CFU of Bifidobacterium animalis) to achieve optimal therapeutic effect, thereby improving glycemic control while simultaneously restoring gut microbiome balance and reducing inflammation
2Quantity of substance
If conventional anti-diabetic drugs are used, then blood glucose levels are reduced, but adverse effects on bacterial microfauna composition occur
Solution Approach 1:
The patent employs probiotics that perform self-service functions within the gut ecosystem. The probiotic bacteria (Lactobacillus acidophilus, Bifidobacterium animalis, Saccharomyces boulardii) autonomously colonize the intestine, metabolize carbohydrates to produce short-chain fatty acids, compete with pathogenic bacteria for resources, and stimulate immune system development. This self-service mechanism effectively lowers blood glucose levels while simultaneously maintaining and stabilizing bacterial microfauna composition without the adverse effects seen with conventional drugs
Solution Approach 2:
The patent merges multiple probiotic strains into a single synergistic composition: Lactobacillus acidophilus (1×10^9 CFU), Bifidobacterium animalis (1×10^9 CFU), and Saccharomyces boulardii (1×10^9 CFU). This combined approach leverages the complementary benefits of each strain—Lactobacillus for lactose metabolism and immune modulation, Bifidobacterium for short-chain fatty acid production, and Saccharomyces for pathogen inhibition—thereby achieving effective glucose control while stabilizing the overall bacterial microfauna composition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition stabilizes glucose levels, reduces insulin resistance, and improves glycemic control, thereby treating and preventing type 2 diabetes and its symptoms by normalizing glucose-insulin mechanisms and altering lipid profiles.
Implementation Method 1
The composition stabilizes glucose levels, reduces insulin resistance, and improves glycemic control by metabolizing glucose
Implementation Method 2
probiotics are substances contained in certain foods, which may modulate the composition of gut microbiome, thereby influencing short-chain fatty acid production
Data Source
AI summary
The present invention provides methods of using a composition comprising one or more bacterial species of the Bacillus genus, rice bran, L-cysteine and a high molecular weight low osmolality carbohydrate for the treatment and/or prevention of type 2 diabetes, pre-diabetes, and/or a symptom thereof in a subject. Further uses of the composition are also provided herein.